2023-504426-19-00
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of GTX-11 in Healthy Subjects
Gat Therapeutics S.L.1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2023年11月27日最近更新:
概览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Gat Therapeutics S.L.
- 入组人数
- 52
- 试验地点
- 1
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Administration
Scientific
Gat Therapeutics S.L.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy Participants2025-521914-25-00Clexio Biosciences Ltd.110
尚未招募
1 期
A phase 1, double-blind, placebo-controlled, randomized, single ascending dose and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of GHF-201 in healthy adult volunteers2024-519813-74-00CCDRD Cooperative Clinical Drug Research and Development AG, GHF-Golden Heart Flower Ltd.32
已完成
1 期
Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in Healthy Participants2023-507018-29-00Teva Branded Pharmaceutical Products R&D Inc.48
招募中
1 期
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.2024-512722-28-00Bioprojet Pharma161
尚未招募
1 期
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus2025-522551-25-00AstraZeneca AB28